Trending...
- The New Trace One Ushers in a New Era for CPG and Retail Product Innovation
- Railway Interchange Organizers Announce Event and Media Partners
- Rally House Expands to Southwest Indiana with New Location
INDIANAPOLIS--(BUSINESS WIRE)--Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2.
"We are pleased to receive a second grant from NIH to support Kovina's research and development efforts. The award from NIAID supports the company's development of therapeutics to treat HPV premalignant infections which represent a global health challenge," said Kristin Sherman, CEO of Kovina Therapeutics.
"Kovina's exciting, novel research proposal merited award after rigorous review by the NIH," said Dr. Elliot Androphy, CSO of Kovina Therapeutics. "Our compounds specifically target an essential HPV protein expressed in early, premalignant, and cancerous pathologies. Inactivation of this protein results in the selective death of HPV infected cells. Our therapeutics are designed to stop HPV premalignant infections before cancer develops and to treat HPV cancers after detection."
More on indianastop.com
About Kovina Therapeutics
Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV). Kovina has assembled a team of scientists and industry leaders with expertise in HPV and small molecule drug design to advance its pipeline of drug candidates. To learn more, visit www.Kovina.com.
Contacts
Kristin Sherman
CEO, Kovina Therapeutics Inc.
317-224-9736
Kristin.Sherman@kovina.com
"We are pleased to receive a second grant from NIH to support Kovina's research and development efforts. The award from NIAID supports the company's development of therapeutics to treat HPV premalignant infections which represent a global health challenge," said Kristin Sherman, CEO of Kovina Therapeutics.
"Kovina's exciting, novel research proposal merited award after rigorous review by the NIH," said Dr. Elliot Androphy, CSO of Kovina Therapeutics. "Our compounds specifically target an essential HPV protein expressed in early, premalignant, and cancerous pathologies. Inactivation of this protein results in the selective death of HPV infected cells. Our therapeutics are designed to stop HPV premalignant infections before cancer develops and to treat HPV cancers after detection."
More on indianastop.com
- PhaseZero Expands CxAnalytics Offering with Generative AI Solutions to power Everyday Efficiency for Global Manufacturing Companies
- Prepare Yourself For A Hair-Raising Musical Journey With Sidow Sobrino's Happy Halloween
- Vantiva Announces it has entered into an agreement with CommScope to acquire CommScope's Home Networks
- Car Accident Lawyer Tempe Accident Law Group
- Larry Hogan Joins Worldwide Speakers Group
About Kovina Therapeutics
Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV). Kovina has assembled a team of scientists and industry leaders with expertise in HPV and small molecule drug design to advance its pipeline of drug candidates. To learn more, visit www.Kovina.com.
Contacts
Kristin Sherman
CEO, Kovina Therapeutics Inc.
317-224-9736
Kristin.Sherman@kovina.com
Filed Under: Business
0 Comments
Latest on indianastop.com
- Robotics and Automation are Driving Demand for Upgraded Warehouse Management Systems concludes new report from the Mobile Robot Directory
- Doctors for Cannabis Regulation Rebrands as Doctors for Drug Policy Reform
- New data reveals 87% Australian adults have experienced a work-related musculoskeletal injury
- Elevance Health's Affiliated 2024 Medicare Advantage Plans Offer Simplicity and Flexibility for Consumers with Affordable Benefits Focused on Whole Health
- NEOM and Maysalward to strengthen young gaming talent with launch of NEOM Game Dev Challenge
- Jeezy, Sexyy Red, Plies, And $hyfromdatre Support The HBCU Community With A Special Concert For NC College Students In Winston-Salem, NC on Oct. 27th
- Rally House Expands to Southwest Indiana with New Location
- Global Luxury Value Exchange, Idoneus, Transitions to 100% IDON Transactions
- USA Green Card Celebrates the State Department's Historic Inclusion of the UK in the DV-2025 Green Card Lottery
- Do Grandparents Make Good Parents?
- Overfuel Acquires 321 Ignition to Advance Automotive Sales Tech
- Cleveland Broadband Selects Axiros' AXESS 5 ACS Software for Advanced Gigabit Internet Service
- Green Office Partner Ranks on the Inc. 5000 Annual List of the Fastest Growing Companies in America
- Office Calgary Inc, announces office expansion plans
- City Awarded $1.87M to Grow South Bend's Urban Forest
- Railway Interchange Organizers Announce Event and Media Partners
- PFW Recap: CHOCHENG Spring/Summer 2024 Les Parapluies De CHOCHENG
- The New Trace One Ushers in a New Era for CPG and Retail Product Innovation
- The Luxe Team at Dale Sorensen Real Estate Brevard Presents 100 Ocean Condominium in Melbourne, Florida
- How to Apply Online for a Loan that pays You in 24 hours